Phase I Safety Pharmacokinetic and Pharmacodynamic study of PF-02341066 a C-Met/HGFR selective Tyrosine Kinase inhibitor administered orally to patients with advanced cancer.
Clinical trial of investigational drug PF-02341066 given by mouth.
IRB Protocol #
SARAH RIPPKE at (720)848-0685 or RIPPKE.SARAH@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility, which may include a tumor biopsy. A treatment period that can last up to 1 year as long as you are responding well to the study drug. A follow up period will consist of a clinic visit 28 days after you stop treatment. // Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s). Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s).